bioavailable EP300/CBP HAT inhibitor

brain penetrant, orally efficacious in xeno.

from HTS and SBDD

ACS Med. Chem. Lett., Apr. 27, 2020

Constellation Pharma., Cambridge, MA


CPI-1612 is a pretty efficient-looking EP300/CBP histone acetyltransferase (HAT) inhibitor tool compound with demonstrated activity in a xenograft model and good higher species PK. While epigenetics targets like HATs have…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: